10x Genomics, Inc. TXG Asset Acquisition, Gain (Loss) Contingent Consideration, Change In Fair Value Disclosure
Asset Acquisition, Gain (Loss) Contingent Consideration, Change In Fair Value Disclosure at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept txg:AssetAcquisitionGainLossContingentConsiderationChangeInFairValueDisclosure.
The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about 10x Genomics, Inc.'s asset acquisition, gain (loss) contingent consideration, change in fair value disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 10x Genomics, Inc.'s asset acquisition, gain (loss) contingent consideration, change in fair value disclosure?
- 10x Genomics, Inc. (TXG) reported asset acquisition, gain (loss) contingent consideration, change in fair value disclosure of $57K in Q1 2026.
- What does asset acquisition, gain (loss) contingent consideration, change in fair value disclosure mean?
- Captures the periodic adjustments to the fair value of contingent consideration liabilities related to past business or asset acquisitions. Fluctuations in this metric reflect changes in the estimated probability or timing of achieving performance-based earn-outs.